One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients?

Abstract

Death from prostate cancer is invariably due to metastatic dissemination and resistance to androgen deprivation therapy, the definition of castration-resistant prostate cancer (CRPC). During the last decade, we dramatically changed our minds concerning the old paradigm that stated prostate cancer is chemoresistant but hormone sensitive for about 2 yr and… (More)
DOI: 10.1016/j.eururo.2014.03.024

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.